Parkinson's Foundation PD GENEration Genetic Registry

Description

Development of a central repository for PD-related genomic data for future research.

Conditions

Parkinson's Disease

Talk to us

Study Overview

On this page

Study Details

Study overview

Development of a central repository for PD-related genomic data for future research.

Parkinson's Foundation PD GENEration Genetic Registry

Parkinson's Foundation PD GENEration Genetic Registry

Condition
Parkinson's Disease
Intervention / Treatment

-

Contacts and Locations

Chandler

MD First Research, Chandler, Arizona, United States, 85286

Phoenix

Barrow Neurological Institute, Phoenix, Arizona, United States, 85013

Fayetteville

University of Arkansas, Fayetteville, Arkansas, United States, 72701

La Jolla

University of California San Diego (UCSD), La Jolla, California, United States, 92093

San Francisco

University of California San Francisco (UCSF), San Francisco, California, United States, 94143

Aventura

Aventura Neurology - Visionary Investigators Network, Aventura, Florida, United States, 33180

Boca Raton

Parkinson's Disease & Movement Disorder Center of Boca Raton, Boca Raton, Florida, United States, 33486

Gainesville

University of Florida, Gainesville, Florida, United States, 32611

Miami

University of Miami, Miami, Florida, United States, 33131

Weston

Cleveland Clinic Weston, Weston, Florida, United States, 33331

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * Study Population 1: PWP (open for recruitment)
  • 1. Meet Movement Disorder Society (MDS) Clinical Diagnostic Criteria for Parkinson's Disease: probable diagnosis.
  • 2. Willingness to undergo genetic testing, and choose to be informed of genetic testing results for GBA, LRRK2 and 5 additional PD related genes (SNCA, VPS35, PRKN, PINK-1, PARK7).
  • 3. Capacity to give full informed consent in writing or electronically, and have read and signed the informed consent forms (ICFs) based on site clinician's determination.
  • 4. Able to perform study activities (including completion of either online, in-person or paper surveys).
  • 1. Family members of Study Population 1 may be invited to participate in the study if confirmatory genetic testing is deemed necessary by the genetic testing laboratory.
  • 1. Diagnosis of an atypical parkinsonian disorder (i.e., multiple system atrophy, progressive supranuclear palsy, dementia with Lewy bodies, corticobasal syndrome), including that due to medications, metabolic disorders, encephalitis, cerebrovascular disease, or normal pressure hydrocephalus.
  • 2. Individuals who have received a blood transfusion within the past 3 months.
  • 3. Individuals who have active hematologic malignancies such as lymphoma or leukemia.
  • 4. Individuals who have had a bone marrow transplant within the past 5 years.
  • 5. Under the age of 18

Ages Eligible for Study

18 Years to

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

Parkinson's Foundation,

James Beck, PhD, PRINCIPAL_INVESTIGATOR, Parkinson's Foundation

Roy N Alcalay, MS, MD, PRINCIPAL_INVESTIGATOR, Tel Aviv Sourasky Medical Center, Columbia University Irving Medical Center

Study Record Dates

2025-06-01